Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

Quantum BioPharma Announces Private Placement
TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it is completing a non-brokered private placement of class A multiple voting shares (“MVS”) at a price of $50 per MVS, for aggregate gross proceeds of up to $600 (the “Offering”). The Company expects that the entirety of the Offering will be subscribed for by the existing holders of MVS.» Mehr auf globenewswire.com
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise» Mehr auf globenewswire.com
Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress
Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies, today released its analysis of Quantum BioPharma Ltd.'s (NASDAQ: QNTM) continued progress across its innovative pipeline of treatments for brain disorders and alcohol health.» Mehr auf newsfilecorp.com

Im letzten Quartal hatte Quantum BioPharma Aktie einen Umsatz von 0,00€ und ein Nettoeinkommen von −7,90 Mio€